Literature DB >> 3039297

Isolation of stable aroA mutants of Salmonella typhi Ty2: properties and preliminary characterisation in mice.

G Dougan, D Maskell, D Pickard, C Hormaeche.   

Abstract

Derivatives of the Salmonella typhi strain Ty2 carrying stable mutations in the aroA gene were isolated. The mutations were generated by transducing an aroA::Tn10 marker into Ty2 and selecting for derivatives which were tetracycline sensitive and dependent on aromatic compounds for growth. Isolates that did not revert to aromatic compound independence at a detectable frequency were obtained. An S. typhimurium derived aroA specific DNA probe was used to demonstrate the presence of DNA rearrangements in the aroA region of the chromosome of some of the S. typhi aroA mutants. Most of these isolates still expressed Vi antigen. Aromatic compound dependent mutants of S. typhi were less virulent in mice than S. typhi Ty2 following intraperitoneal challenge with bacteria suspended in mucin. Mice immunised with one of these mutants, named WBL85-1, were protected against a potentially lethal challenge of S. typhi Ty2.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039297     DOI: 10.1007/BF00331607

Source DB:  PubMed          Journal:  Mol Gen Genet        ISSN: 0026-8925


  27 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

Review 2.  Molecular cloning of schistosome genes.

Authors:  D W Taylor; J S Cordingley; D W Dunne; K S Johnson; W J Haddow; C E Hormaeche; V Nene; A E Butterworth
Journal:  Parasitology       Date:  1986       Impact factor: 3.234

3.  Infectivity and antigenicity of streptomycin-dependent Salmonella typhosa.

Authors:  M Reitman
Journal:  J Infect Dis       Date:  1967-02       Impact factor: 5.226

4.  A seven-year field trial of two typhoid vaccines in Guyana.

Authors:  M T Ashcroft; B Singh; C C Nicholson; J M Ritchie; E Sorryan; F Williams
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

5.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

6.  A small cosmid for efficient cloning of large DNA fragments.

Authors:  B Hohn; J Collins
Journal:  Gene       Date:  1980-11       Impact factor: 3.688

7.  Positive selection for loss of tetracycline resistance.

Authors:  B R Bochner; H C Huang; G L Schieven; B N Ames
Journal:  J Bacteriol       Date:  1980-08       Impact factor: 3.490

8.  Genetic analysis of K88-mediated adhesion of enterotoxigenic Escherichia coli.

Authors:  M Kehoe; R Sellwood; P Shipley; G Dougan
Journal:  Nature       Date:  1981-05-14       Impact factor: 49.962

9.  Controlled field trial of a high-dose oral killed typhoid vaccine in India.

Authors:  C S Chuttani; K Prakash; P Gupta; V Grover; A Kumar
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

10.  Salmonella typhimurium aroA mutants as carriers of the Escherichia coli heat-labile enterotoxin B subunit to the murine secretory and systemic immune systems.

Authors:  D J Maskell; K J Sweeney; D O'Callaghan; C E Hormaeche; F Y Liew; G Dougan
Journal:  Microb Pathog       Date:  1987-03       Impact factor: 3.738

View more
  14 in total

Review 1.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

2.  Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers.

Authors:  J X Bao; J D Clements
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 3.  Oral vaccination.

Authors:  G Dougan; D Maskell; D O'Callaghan; S Chatfield; I Charles; C Hormaeche
Journal:  Antonie Van Leeuwenhoek       Date:  1988       Impact factor: 2.271

4.  The Salmonella enterica serovar Typhi tsx gene, encoding a nucleoside-specific porin, is essential for prototrophic growth in the absence of nucleosides.

Authors:  Sergio A Bucarey; Nicolás A Villagra; Mara P Martinic; A Nicole Trombert; Carlos A Santiviago; Nancy P Maulén; Philip Youderian; Guido C Mora
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Construction of delta aroA his delta pur strains of Salmonella typhi.

Authors:  M F Edwards; B A Stocker
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

6.  Salmonella enterica serovar typhimurium trxA mutants are protective against virulent challenge and induce less inflammation than the live-attenuated vaccine strain SL3261.

Authors:  S E Peters; G K Paterson; E S D Bandularatne; H C Northen; S Pleasance; C Willers; J Wang; A K Foote; F Constantino-Casas; T J Scase; B A Blacklaws; C E Bryant; P Mastroeni; I G Charles; D J Maskell
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

7.  Systematic annotation and analysis of "virmugens"-virulence factors whose mutants can be used as live attenuated vaccines.

Authors:  Rebecca Racz; Monica Chung; Zuoshuang Xiang; Yongqun He
Journal:  Vaccine       Date:  2012-12-06       Impact factor: 3.641

8.  The Mycobacterium tuberculosis shikimate pathway genes: evolutionary relationship between biosynthetic and catabolic 3-dehydroquinases.

Authors:  T Garbe; S Servos; A Hawkins; G Dimitriadis; D Young; G Dougan; I Charles
Journal:  Mol Gen Genet       Date:  1991-09

9.  Molecular characterization of the Salmonella enterica serovar Typhi Vi-typing bacteriophage E1.

Authors:  Derek Pickard; Nicholas R Thomson; Stephen Baker; John Wain; Mercedes Pardo; David Goulding; Nancy Hamlin; Jyoti Choudhary; John Threfall; Gordon Dougan
Journal:  J Bacteriol       Date:  2008-01-11       Impact factor: 3.490

10.  Cloning and nucleotide sequence of the aroA gene of Bordetella pertussis.

Authors:  D J Maskell; P Morrissey; G Dougan
Journal:  J Bacteriol       Date:  1988-06       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.